Preeclampsia Epidemiology

Key Highlights:

• Preeclampsia, is a pregnancy-related condition characterized by the new onset of high blood pressure, typically accompanied by protein in the urine. It most commonly develops after 20 weeks of gestation, often occurring close to term. 
• Preeclampsia can develop subtly, often without noticeable symptoms in the early stages. When present, symptoms may include persistent swelling of the face or hands, unrelenting headaches, visual disturbances and discomfort or pain in the upper abdomen or shoulder.
• Risk factors for preeclampsia include a history of the condition in a previous pregnancy, carrying multiple foetuses such as twins or triplets, and chronic hypertension. Other contributing factors include being pregnant for the first time, having a pregnancy more than ten years after a previous one, and having a body mass index (BMI) over 30.
• Diagnosis of preeclampsia involves identifying pregnancy-induced hypertension and conducting laboratory tests. These include a urinalysis to detect proteinuria, a complete blood count to evaluate for thrombocytopenia, and a comprehensive metabolic panel to assess liver function and renal insufficiency.
• Most cases of Preeclampsia in the United States were in the 25-29yrs age group, with 66,000 cases in 2024.
• Spain accounted for the lowest number of diagnosed incidence cases in 2024 with 11,000 cases

DelveInsight’s “Preeclampsia – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Preeclampsia, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The table given below further depicts the key segments provided in the report:

Preeclampsia Disease Understanding 

Preeclampsia Overview, and Diagnosis

Hypertensive disorders of pregnancy constitute a leading cause of maternal and perinatal mortality worldwide. Preeclampsia, with or without severe features, is a disorder of pregnancy associated with new-onset hypertension, usually with accompanying proteinuria, which occurs most often after 20 weeks of gestation and frequently near term. This disease represents a spectrum of hypertensive disease in pregnancy, beginning with gestational hypertension and progressing to develop severe features, ultimately leading to its more severe manifestations, such as eclampsia and HELLP (hemolysis, elevated liver enzymes, low platelet count) syndrome. Early diagnosis and prompt management are essential for preventing both maternal and neonatal complications through symptomatic management and delivery planning.

In addition to elevated blood pressure, preeclampsia may present with various signs and symptoms that indicate involvement of multiple organ systems. These can include the presence of excess protein in the urine or other indicators of kidney dysfunction, a reduced platelet count (thrombocytopenia), and elevated liver enzymes suggestive of hepatic impairment. Neurological symptoms such as severe headaches and visual disturbances—including temporary vision loss, blurred vision, or sensitivity to light—may also occur. Respiratory symptoms like shortness of breath can result from fluid accumulation in the lungs. Abdominal pain, typically located in the upper right quadrant beneath the ribs, as well as nausea or vomiting, may also be present. While weight gain and swelling are common in normal pregnancies, the sudden onset of significant weight gain or noticeable swelling—especially in the face and hands—can be indicative of preeclampsia and warrants further evaluation.

After a thorough history and physical examination, patients exhibiting signs and symptoms of preeclampsia should undergo prompt diagnostic evaluation. This includes laboratory testing for pregnancy-induced hypertension, consisting of urinalysis to evaluate the presence of proteinuria (either with a urine dipstick result ≥2+ [if other methods are not readily available], a 24-hour urine collection sample significant for ≥300 mg, or a urine protein to creatinine ratio significant of 0.3 or greater). A complete blood count to evaluate for thrombocytopenia (defined as a platelet count <100 K/mm), a complete metabolic panel to assess for impaired liver function (with liver enzymes more than 2 times the upper limit of normal), and renal insufficiency (defined as a serum concentration ≥1.1 mg/dL, or levels 2 times greater than baseline). All abnormal laboratory findings must exclude any pre existing aberrations or secondary causes for abnormalities to be significant for diagnosis.

Preeclampsia Epidemiology

The Preeclampsia epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total incidence cases of preeclampsia, Age-specific cases of preeclampsia, Subtype-specific cases of preeclampsia, Severity-specific cases of preeclampsia, in the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2021 to 2034.

• In 2024, there were around 334,000 diagnosed incidence cases of preeclampsia in the 7MM, which are expected to rise by 2034.
• In 2024, the US recorded a higher incidence of preeclampsia cases in the 25-29yrs age group, with around 66,500 cases, followed by the ≥39yrs age group, which accounted for approximately 65,700 cases.
• In 2024, late-onset preeclampsia represented the majority of cases, with approximately 116,800 reported within the EU4 and the UK and there were around 13,000 documented cases of early-onset preeclampsia during the same year.
• In 2024, the Japan reported the highest number of mild cases of preeclampsia, followed by severe cases, with around 14,000 and 4,700 cases, respectively.

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of Preeclampsia, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
• A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.

Preeclampsia Report Insights

• Patient Population
• Country-wise Epidemiology Distribution

Preeclampsia Report Key Strengths

• Ten-year Forecast
• The 7MM Coverage 
• Preeclampsia Epidemiology Segmentation

Preeclampsia Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

FAQs

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Preeclampsia? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Preeclampsia?
• What is the historical and forecasted Preeclampsia patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What is the diagnostic pattern of Preeclampsia?
• Which clinical factors will affect Preeclampsia?
• Which factors will affect the increase in the diagnosis of Preeclampsia?

Reasons to buy

• Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the change in Preeclampsia cases in varying geographies over the coming years.
• A detailed overview of total incident cases of Preeclampsia, total diagnosed incident cases of Preeclampsia, Age-specific cases of Preeclampsia, Subtype-specific cases of Preeclampsia Severity-specific cases of Preeclampsia is included.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.